Specialist healthcare group, Ark Therapeutics, and serious diseases therapies developer PsiOxus Therapeutics, said their partnership has successfully achieved its first milestone.
The firms have manufactured PsiOxus's colorectal cancer product, and as a result PsiOxus has initiated final pre-clinical toxicology studies of the product.
Martyn Williams, Chief Executive Officer of Ark said: "We are delighted that our early success with ColoAd1 will enable the development of this exciting product to move forward as planned and we look forward to continuing to provide full support to our partner as their programme moves into the clinic."
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The share price rose 4.69% to 3.35p by 15:17.
__
NR
-
RICS: Buyer demand and sales surge - but how could the Budget affect the housing market?The Royal Institute of Chartered Surveyors reports a positive shift in the UK property market, but adds that next month’s Budget is “keeping the mood in check”
-
Big houses ‘driving the housing market’ as sellers ‘seek to beat Budget tax rises’, Rightmove data suggestsNews The number of big houses being listed on the property website has gone up by a double-digit percentage across most regions of Great Britain.
